ArticleOncogene2023
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Open access · hybridFull text read
In one paragraph
Article in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.BMC cancer · 2025Pooled it
- Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.British journal of cancer · 2026Article
- An O-glycosylation-based prognostic signature for biochemical recurrence in prostate cancer identifiesTranslational andrology and urology · 2026Article
- Cancer-associated alterations in O-GalNAc glycosylation.Glycobiology · 2026Review
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- GALNT7-induced O-glycosylation of NUP50 activates fatty acid β-oxidation to promote lung adenocarcinoma metastasis.The Journal of biological chemistry · 2026Article
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- GALNT7 promotes the malignant progression of gastrointestinal stromal tumors by regulating KIT O-GalNAc glycosylation.Precision clinical medicine · 2026Article
- Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer.Pathology international · 2026Article
- Glycosaminoglycans in tissue regeneration: Insights into glycobiology and their biomedical application.Bioactive materials · 2026Review
- Nonlinear kernel-based high-dimensional inference for set-based genetic association studies.Briefings in bioinformatics · 2026Article
- Glycan atlassing enables functional tracing of cell state.Nature nanotechnology · 2026Article
- The Critical Role of GALNTs-Regulated O-GalNAc Glycosylation in Cancer Malignancy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancer.bioRxiv : the preprint server for biology · 2026Article
- LightGBM-guided discovery of mechanistic biomarkers in thyroid cancer: GALNT7 and SKP1P1 emerge as therapeutic targets.Discover oncology · 2026Article
- Inhibition of GALNT7 suppresses cell proliferation and invasiveness while elevating cell apoptosis via the inactivation of the AKT pathway in non-small cell lung cancer.BMJ open respiratory research · 2026Article
- Glycosylation-Related Gene Signature Identifies MFNG as a Key Driver of Proliferation and Metastasis in Colorectal Cancer.OncoTargets and therapy · 2026Article
- Golgi Drivers of Cancer.Sub-cellular biochemistry · 2026Review
- GalNAc-Transferases in Cancer.Biomedicines · 2025Review
- Targeting the cancer glycocalyx in salivary duct carcinoma: tumor-associated mucin 1 (Tn-MUC1) as a novel cell surface marker.The journal of pathology. Clinical research · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
59 authors at 18 institutions in 6 countries.
Emma ScottNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Kirsty HodgsonNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Beatriz CalleThe Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT, London, UK.ORCID 0000-0002-9893-9803
Helen TurnerCellular Pathology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.
Kathleen CheungNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Abel BermudezCanary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
Fernando Jose Garcia MarquesCanary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
Hayley PyeMolecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.ORCID 0000-0001-7042-5416
Edward Christopher YoNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Khirul IslamDepartment of Life Technologies, Division of Biotechnology, University of Turku, Turku, Finland.
Htoo Zarni OoDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
Urszula L McClurgInstitute for Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.
Laura WilsonNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Huw ThomasNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Fiona M FrameCancer Research Unit, Department of Biology, University of York, Heslington, North Yorkshire, YO10 5DD, UK.
Margarita Orozco-MorenoNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Kayla BastianNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Hector M ArredondoThe Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
Chloe RoustanStructural Biology Science Technology Platform, The Francis Crick Institute, NW1 1AT, London, UK.
Melissa Anne GraySarafan Chem-H and Departemnt of Chemistry, Stanford University, 424 Santa Teresa St, Stanford, CA, 94305, USA.
Lois KellyNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Aaron TolsonNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Ellie MellorNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Gerald HysenajNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Emily Archer GoodeNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Rebecca GarnhamNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Adam DuxfieldNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Susan HeaveyMolecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
Urszula Stopka-FarooquiMolecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
Aiman HaiderDepartment of Pathology, UCLH NHS Foundation Trust, London, UK.
Alex FreemanDepartment of Pathology, UCLH NHS Foundation Trust, London, UK.
Saurabh SinghUCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
Edward W JohnstonUCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
Shonit PunwaniUCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
Bridget KnightNIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Paul McCullaghDepartment of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
John McGrathExeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Malcolm CrundwellExeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Lorna HarriesInstitute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
Denisa BogdanDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
Daniel WestabyDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
Gemma FowlerDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
Penny FlohrDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
Wei YuanDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
Adam SharpDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.ORCID 0000-0002-3740-1612
Johann de BonoDivision of Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK.
Norman J MaitlandCancer Research Unit, Department of Biology, University of York, Heslington, North Yorkshire, YO10 5DD, UK.ORCID 0000-0003-1607-9035
Simon WisnovskyUniversity of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, V6T 1Z3, Canada.
Carolyn R BertozziHoward Hughes Medical Institute, 424 Santa Teresa St, Stanford, CA, 94305, USA.ORCID 0000-0003-4482-2754
Rakesh HeerNewcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Ramon Hurtado GuerreroUniversity of Zaragoza, Mariano Esquillor s/n, Campus Rio Ebro, Edificio I+D, Zaragoza, Spain; Fundación ARAID, 50018, Zaragoza, Spain.ORCID 0000-0002-3122-9401
Mads DaugaardDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
Janne LeivoDepartment of Life Technologies, Division of Biotechnology, University of Turku, Turku, Finland.
Hayley WhitakerMolecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.ORCID 0000-0002-2695-0202
Sharon PitteriCanary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.ORCID 0000-0002-3119-873X
Ning WangThe Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
David J ElliottNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK.
Benjamin SchumannThe Chemical Glycobiology Laboratory, The Francis Crick Institute, NW1 1AT, London, UK.ORCID 0000-0001-5504-0147
Jennifer MunkleyNewcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, NE1 3BZ, UK. Jennifer.munkley@ncl.ac.uk.ORCID 0000-0002-8631-4531
Newcastle University · GBUniversity College London · GBInstitute of Cancer Research · GBRoyal Devon & Exeter NHS Foundation Trust · GBStanford University · USRoyal Marsden NHS Foundation Trust · GBThe Francis Crick Institute · GBUniversity of British Columbia · CAUniversity College Hospital · GBUniversity of Sheffield · GBUniversity of Turku · FIYorkshire Cancer Research · GBHoward Hughes Medical Institute · USNewcastle upon Tyne Hospitals NHS Foundation Trust · GBRoyal Victoria Infirmary · GBUniversity of Copenhagen · DKUniversity of Exeter · GBUniversity of Liverpool · GB
Funding
ZINC DEFICIENCY &PROTEIN EXPRESSION IN RAT OLFACTORY BULBSP41RR005351 · NCRR · UNIVERSITY OF GEORGIA (UGA) · PI AZADI, PARASTOO · 1989 to 2011
$18.4MStanford Molecular and Cellular Characterization LaboratoryU01CA196387 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D. · 2015 to 2020
$5.2MInvestigating the Surface GlycoproteomeR01CA200423 · NCI · STANFORD UNIVERSITY · PI Carolyn Bertozzi · 2015 to 2026
$3.8MMedical Research Council MR/M018318/1Medical Research Council MR/W018217/1NCI NIH HHS R01 CA200423NCI NIH HHS U01 CA196387NCRR NIH HHS P41 RR005351Prostate Cancer UK RIA16-ST2-011Wellcome Trust FC001749
Abstract
Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need to improve how clinically significant prostate cancer is diagnosed and develop new treatments for advanced disease. Aberrant glycosylation is a hallmark of cancer implicated in tumour growth, metastasis, and immune evasion. One of the key drivers of aberrant glycosylation is the dysregulated expression of glycosylation enzymes within the cancer cell. Here, we demonstrate using multiple independent clinical cohorts that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue. We show GALNT7 can identify men with prostate cancer, using urine and blood samples, with improved diagnostic accuracy than serum PSA alone. We also show that GALNT7 levels remain high in progression to castrate-resistant disease, and using in vitro and in vivo models, reveal that GALNT7 promotes prostate tumour growth. Mechanistically, GALNT7 can modify O-glycosylation in prostate cancer cells and correlates with cell cycle and immune signalling pathways. Our study provides a new biomarker to aid the diagnosis of clinically significant disease and cements GALNT7-mediated O-glycosylation as an important driver of prostate cancer progression.
Indexed as
Prostatic NeoplasmsGlycosylationHumansMaleSignal TransductionTranscriptional ActivationUp-Regulation
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
measurements read29
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.